Leerink raises 89bio stock target to $37 on NASH study optimism
Leerink Partners analyst Thomas Smith adjusted the price target for 89bio Inc . (NASDAQ:ETNB) to $37 from $34, while ...
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $862.00 at Leerink Partners
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price decreased by equities research analysts at Leerink Partners from $980.00 to $862.00 in a research note issued on Tuesday.
Leerink Partnrs Estimates AbbVie’s Q1 Earnings (NYSE:ABBV)
Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of AbbVie in a research note issued to investors on Monday, February 3rd. Leerink ...
Alto Neuroscience announces $75 million ATM offering
Alto Neuroscience , Inc. (NYSE:ANRO), a pharmaceutical company currently trading at $4.18 per share, has entered into a Sales Agreement with Leerink Partners LLC, initiating an "at the market" ...
Business Insider17d
Leerink Partners Remains a Buy on AnaptysBio (ANAB)
In a report released on January 16, David Risinger from Leerink Partners maintained a Buy rating ... Earlier this month, Ecor1 Capital, Llc, a Director at ANAB bought 85,098.00 shares for a ...
Nasdaq1mon
Leerink Partners Upgrades Align Technology (WBAG:ALGN)
Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (WBAG:ALGN) from Market Perform to Outperform. There are 1,519 funds or institutions reporting ...
Nasdaq1mon
Leerink Partners Upgrades Align Technology (LSE:0HCK)
Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (LSE:0HCK) from Market Perform to Outperform. There are 1,519 funds or institutions reporting ...
FiercePharma13d
After slow rollout, Merck's Winrevair poised for 'strong uptake' in 2025: Leerink
Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at Leerink Partners believe that Merck’s Winrevair “should have ...
Hold Rating Maintained on Zentalis Pharmaceuticals Amid Uncertainties and Regulatory Scrutiny
In a report released on January 29, Andrew Berens from Leerink Partners maintained a Hold rating on Zentalis Pharmaceuticals (ZNTL – Research ...
Investing1mon
Leerink reiterates Outperform on Axsome stock despite FDA uncertainty for Auvelity
On Monday, Leerink Partners sustained their Outperform rating and $110.00 price target for Axsome Therapeutics (NASDAQ:AXSM) shares. The firm's stance comes in the wake of recent clinical trial ...
Thryv Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference in Miami, FL
PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is pleased to announce its participation in the 2025 Leerink Partn ...